Okano Motohiko, Gross Thomas G
Department of Microbiology, Center for Infectious Diseases Control, Hokkaido Institute of Public Health, Kita-ku, Sapporo, Japan.
Expert Rev Anti Infect Ther. 2007 Jun;5(3):403-13. doi: 10.1586/14787210.5.3.403.
Epstein-Barr virus (EBV) is an ubiquitous human herpesvirus. Primary infection is generally subclinical but in certain circumstances, such as in patients with either hereditary or secondary immunodeficiency, EBV infection may cause overt disease that is often lethal. Strategies for the prophylaxis and treatment of these potentially life-threatening complications of EBV infection have advanced dramatically. They include immunological-based approaches targeted at EBV-infected cells, as well as improvement in the treatment of the underlying and predisposing disease. This review will discuss EBV biology and immune events that occur in both immunocompetent and immunocompromised individuals and introduce the novel prophylactic and therapeutic strategies for EBV-associated life-threatening diseases.
爱泼斯坦-巴尔病毒（EBV）是一种普遍存在的人类疱疹病毒。原发性感染通常为亚临床感染，但在某些情况下，如遗传性或继发性免疫缺陷患者中，EBV感染可能导致明显疾病，且往往是致命的。预防和治疗EBV感染这些潜在危及生命并发症的策略有了显著进展。它们包括针对EBV感染细胞的基于免疫的方法，以及改善潜在和诱发疾病的治疗。本综述将讨论在免疫功能正常和免疫功能低下个体中发生的EBV生物学和免疫事件，并介绍针对EBV相关危及生命疾病的新型预防和治疗策略。
